Articlenpj biomedical innovations2026
Comparative study of in vitro osteoarthritic inflammatory models during chondrogenic differentiation in pellet culture.
Article in npj biomedical innovations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Osteoarthritis (OA) treatments address pain rather than disease progression. A limitation of current in vitro testing of tissue constructs is evaluation under ideal conditions rather than inflammatory, osteoarthritic environments. To address this limitation, we evaluated mesenchymal stromal cells (MSCs) in simulated OA conditions. Our goals are to determine the effect of an OA environment on MSC pellets exposed to transforming growth factor-beta-3 (TGF-β3) and to compare OA cytokine models of tumor necrosis factor-alpha (TNF-α) and oncostatin M (OSM), TNF-α alone, or interleukin-1 beta (IL-1β) alone. Three controls were evaluated: (1) negative and (2) positive for cartilage matrix production, and (3) OSM. The IL-1β, TNF-α, and OSM + TNF-α groups all had reduced cartilage matrix production, whereas OSM showed intermediate deposition. OSM had the highest MMP-13 expression, followed by IL-1β and OSM + TNF-α. OSM + TNF-α had a sustained inflammatory response with elevated IL-6 and IL-8 gene and protein expression. Overall, MSC response to OSM + TNF-α or IL-1β alone mimicked disease phenotypes more closely than TNF-α alone. The results highlight that MSCs exposed to chondrogenic growth factors do not result in significant cartilage matrix formation in the inflammatory environment. Thus, there is a need for tissue-engineered constructs that protect cells from inflammation and promote cartilage formation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.